{"id":"https://openalex.org/W2013414825","doi":"https://doi.org/10.1111/1468-0408.00025","title":"The Pharmaceutical Price Regulation Scheme","display_name":"The Pharmaceutical Price Regulation Scheme","publication_year":1997,"publication_date":"1997-02-01","ids":{"openalex":"https://openalex.org/W2013414825","doi":"https://doi.org/10.1111/1468-0408.00025","mag":"2013414825"},"language":"en","primary_location":{"id":"doi:10.1111/1468-0408.00025","doi":"https://doi.org/10.1111/1468-0408.00025","is_oa":false,"landing_page_url":"https://doi.org/10.1111/1468-0408.00025","pdf_url":null,"source":{"id":"https://openalex.org/S178634671","display_name":"Financial Accountability and Management","issn_l":"0267-4424","issn":["0267-4424","1468-0408"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","fnege-4","jufo-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Financial Accountability & Management","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091682905","display_name":"Alan Earl\u2010Slater","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I56007636","display_name":"Keele University","ror":"https://ror.org/00340yn33","country_code":"GB","type":"education","lineage":["https://openalex.org/I56007636"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Alan Earl\u2010Slater","raw_affiliation_strings":["Senior Lecturer, Department of Medicines Management, University of Keele and Associate Member of the Regulatory Policy Institute, Oxford"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Lecturer, Department of Medicines Management, University of Keele and Associate Member of the Regulatory Policy Institute, Oxford","institution_ids":["https://openalex.org/I56007636"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5091682905"],"corresponding_institution_ids":["https://openalex.org/I56007636"],"apc_list":{"value":2900,"currency":"USD","value_usd":2900},"apc_paid":null,"fwci":2.0313,"has_fulltext":false,"cited_by_count":47,"citation_normalized_percentile":{"value":0.87284106,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"13","issue":"1","first_page":"35","last_page":"54"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T14396","display_name":"Healthcare Regulation","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-price-regulation","display_name":"drug price regulation","score":0.7559999823570251},{"id":"https://openalex.org/keywords/price-caps","display_name":"price caps","score":0.7850000262260437},{"id":"https://openalex.org/keywords/regulatory-accountability","display_name":"regulatory accountability","score":0.597000002861023},{"id":"https://openalex.org/keywords/impact-analysis","display_name":"impact analysis","score":0.8050000071525574},{"id":"https://openalex.org/keywords/eu-law-compliance","display_name":"EU law compliance","score":0.8009999990463257}],"concepts":[{"id":"https://openalex.org/C2776007630","wikidata":"https://www.wikidata.org/wiki/Q2798912","display_name":"Accountability","level":2,"score":0.6118384599685669},{"id":"https://openalex.org/C2778137410","wikidata":"https://www.wikidata.org/wiki/Q2732820","display_name":"Government (linguistics)","level":2,"score":0.5893635153770447},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.5517308115959167},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.5395544767379761},{"id":"https://openalex.org/C181622380","wikidata":"https://www.wikidata.org/wiki/Q26911","display_name":"Profit (economics)","level":2,"score":0.5247119665145874},{"id":"https://openalex.org/C2984066494","wikidata":"https://www.wikidata.org/wiki/Q428148","display_name":"Government regulation","level":3,"score":0.478739470243454},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.4519382417201996},{"id":"https://openalex.org/C121955636","wikidata":"https://www.wikidata.org/wiki/Q4116214","display_name":"Accounting","level":1,"score":0.3629233241081238},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.33061426877975464},{"id":"https://openalex.org/C40700","wikidata":"https://www.wikidata.org/wiki/Q1411783","display_name":"Industrial organization","level":1,"score":0.3285454511642456},{"id":"https://openalex.org/C175444787","wikidata":"https://www.wikidata.org/wiki/Q39072","display_name":"Microeconomics","level":1,"score":0.16423535346984863},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.1347675323486328},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.08195596933364868},{"id":"https://openalex.org/C191935318","wikidata":"https://www.wikidata.org/wiki/Q148","display_name":"China","level":2,"score":0.0},{"id":"https://openalex.org/C41895202","wikidata":"https://www.wikidata.org/wiki/Q8162","display_name":"Linguistics","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1111/1468-0408.00025","doi":"https://doi.org/10.1111/1468-0408.00025","is_oa":false,"landing_page_url":"https://doi.org/10.1111/1468-0408.00025","pdf_url":null,"source":{"id":"https://openalex.org/S178634671","display_name":"Financial Accountability and Management","issn_l":"0267-4424","issn":["0267-4424","1468-0408"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","fnege-4","jufo-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Financial Accountability & Management","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1979688872","https://openalex.org/W2121397216","https://openalex.org/W2540007457","https://openalex.org/W7099983750","https://openalex.org/W2076190909","https://openalex.org/W160093108","https://openalex.org/W4239839959","https://openalex.org/W1994738365","https://openalex.org/W2009966338","https://openalex.org/W2418906929"],"abstract_inverted_index":{"The":[0,43,73,83],"UK":[1,110],"government":[2,123],"conditions":[3],"the":[4,32,68,78,117,132,151,160],"pharmaceutical":[5,44],"environment":[6],"with":[7,80],"a":[8,86,91],"combination":[9],"of":[10,88,93],"micro":[11],"and":[12,15,55,76,126,128,142,153],"macro":[13],"policies":[14],"pressures.":[16],"Drug":[17],"profits":[18],"have":[19],"been":[20],"controlled":[21],"since":[22],"1969":[23],"but":[24,60],"it":[25],"was":[26],"only":[27],"in":[28,105,159],"May":[29],"1996":[30],"that":[31,67],"first":[33],"report":[34],"on":[35,97],"these":[36,144],"regulations":[37],"were":[38],"made":[39],"available":[40],"by":[41,101],"government.":[42],"price":[45,53],"regulation":[46,57,69,133],"scheme":[47],"(PPRS)":[48],"is":[49,66,99,134],"obviously":[50],"complex,":[51],"synthesising":[52],"cap":[54],"profit":[56],"for":[58,113,157],"example,":[59],"what":[61,98],"makes":[62],"matters":[63],"more":[64],"difficult":[65],"has":[70],"serious":[71],"problems.":[72],"paper":[74,147],"identifies":[75],"discusses":[77],"problems":[79,84,104,145],"PPRS":[81],"regulation.":[82],"are:":[85],"lack":[87,92],"impact":[89],"analysis;":[90],"accountability;":[94],"no":[95],"agreement":[96],"meant":[100],"\u2018reasonable":[102],"profits\u2019;":[103],"apportioning":[106],"R&D":[107],"costs":[108],"to":[109,122,137,149],"sales;":[111],"disincentives":[112],"international":[114],"trade;":[115],"whether":[116,129],"drug":[118],"companies'":[119],"accounts":[120],"submitted":[121],"are":[124],"true":[125],"fair;":[127],"or":[130],"not":[131],"legal":[135],"according":[136],"EU":[138],"law.":[139],"By":[140],"identifying":[141],"discussing":[143],"this":[146],"aims":[148],"open":[150],"debate":[152],"provide":[154],"an":[155],"opportunity":[156],"improvements":[158],"regulations.":[161]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2016-06-24T00:00:00"}